112 related articles for article (PubMed ID: 3166483)
41. [Field trial for the early detection of patients with ovarian cancer--discrimination of ovarian cancer patients by the statistical analysis using Mahalanobis' generalized distance].
Kobayashi H; Sumimoto K; Terao T; Kawashima Y; Okada K
Nihon Sanka Fujinka Gakkai Zasshi; 1992 Feb; 44(2):174-80. PubMed ID: 1372032
[TBL] [Abstract][Full Text] [Related]
42. [Clinical value of serum CA19-9, CA125 and CP2 in mucinous ovarian tumor: a retrospective study of 273 patients].
Dong L; Cui H; Li XP; Sun LF; Chang XH; Liang XD; Zhu HL
Zhonghua Fu Chan Ke Za Zhi; 2008 Jan; 43(1):5-8. PubMed ID: 18366923
[TBL] [Abstract][Full Text] [Related]
43. The use of mucin-specific monoclonal antibodies and lectins in the detection of tumor-associated serum markers in gynecological cancer.
Devine PL; McGuckin MA; Ramm LE; Harada H; Ward BG
Cancer Biochem Biophys; 1993 Sep; 13(4):221-38. PubMed ID: 8521372
[TBL] [Abstract][Full Text] [Related]
44. [A fundamental and clinical investigation of cancer antigen 130 (CA 130) in the field of obstetrics and gynecology].
Inaba N; Okajima Y; Ota Y; Fukazawa I; Yamaguchi T; Sato N; Sudo H; Milanga M; Takamizawa H; Fujii S
Nihon Gan Chiryo Gakkai Shi; 1989 Oct; 24(10):2426-35. PubMed ID: 2614181
[TBL] [Abstract][Full Text] [Related]
45. Afamin and apolipoprotein A-IV: novel protein markers for ovarian cancer.
Dieplinger H; Ankerst DP; Burges A; Lenhard M; Lingenhel A; Fineder L; Buchner H; Stieber P
Cancer Epidemiol Biomarkers Prev; 2009 Apr; 18(4):1127-33. PubMed ID: 19336561
[TBL] [Abstract][Full Text] [Related]
46. [Basic and clinical evaluation of an immunoradiometric competitive inhibition assay for 2----6 sialyl Lewis a antigen--2. Evaluation of clinical significance].
Imura H; Takahashi T; Matsuda T; Yoshida O; Ohkura H; Seitetsu Y; Seino Y; Ishii M; Kuwabara M; Ariyoshi Y
Gan To Kagaku Ryoho; 1989 Jun; 16(6):2203-12. PubMed ID: 2660749
[TBL] [Abstract][Full Text] [Related]
47. [Serum CA125 in malignant ovarian tumor--periodical monitoring and correlation with other tumor markers].
Kawai M; Yamashita H; Hayashi T; Kamiya N; Kakihara M; Arii Y
Nihon Sanka Fujinka Gakkai Zasshi; 1986 Mar; 38(3):402-10. PubMed ID: 3457877
[TBL] [Abstract][Full Text] [Related]
48. Preoperative plasma osteopontin level as a biomarker complementary to carbohydrate antigen 125 in predicting ovarian cancer.
Nakae M; Iwamoto I; Fujino T; Maehata Y; Togami S; Yoshinaga M; Douchi T
J Obstet Gynaecol Res; 2006 Jun; 32(3):309-14. PubMed ID: 16764622
[TBL] [Abstract][Full Text] [Related]
49. [Tumor markers of ovarian cancer].
Nozawa S
Rinsho Byori; 1992 Apr; 40(4):349-53. PubMed ID: 1593759
[TBL] [Abstract][Full Text] [Related]
50. [Basic and clinical evaluation of an immunoradiometric competitive inhibition assay for sialyl TN antigen: (2). Evaluation of clinical significance. STN Study Group].
Imura H; Mori T; Ohkura H; Ishii M; Ariyoshi H; Endo J; Kitao M; Takeda I; Kobayashi H; Inoue M
Gan To Kagaku Ryoho; 1989 Sep; 16(9):3221-30. PubMed ID: 2571323
[TBL] [Abstract][Full Text] [Related]
51. [Serum CA125, CA19-9 and TPA in the diagnostic approach to neoplastic pathology of the ovary].
Gadducci A; Bartolini T; Ferdeghini M; Facchini V; Bianchi R; Fioretti P
Minerva Ginecol; 1987 Sep; 39(9):601-6. PubMed ID: 3479708
[No Abstract] [Full Text] [Related]
52. [Clinical significance of CA19-9 for endometriosis].
Watanabe J; Johboh T; Hata H; Kuramoto H
Nihon Sanka Fujinka Gakkai Zasshi; 1990 Feb; 42(2):155-61. PubMed ID: 2313144
[TBL] [Abstract][Full Text] [Related]
53. [Clinical value of a new serum tumor marker CA602 in ovarian cancers].
Suzuki M; Sekiguchi I; Ohwada M; Aida I; Tamada T
Nihon Gan Chiryo Gakkai Shi; 1990 Jul; 25(7):1454-60. PubMed ID: 2170549
[TBL] [Abstract][Full Text] [Related]
54. [Clinical significance of galactosyltransferase associated with tumor (GAT), a new tumor marker for ovarian cancer--with special reference to the discrimination between ovarian cancer and endometriosis].
Nozawa S; Udagawa Y; Ito K; Nishimura H; Yakushiji M; Shiota M; Noda K; Yajima M; Ohkura H; Murae M
Gan To Kagaku Ryoho; 1994 Mar; 21(4):507-16. PubMed ID: 8129392
[TBL] [Abstract][Full Text] [Related]
55. Comparative analysis of CA125, tissue polypeptide specific antigen, and soluble interleukin-2 receptor alpha levels in sera, cyst, and ascitic fluids from patients with ovarian carcinoma.
Sedlaczek P; Frydecka I; Gabryś M; Van Dalen A; Einarsson R; Harłozińska A
Cancer; 2002 Nov; 95(9):1886-93. PubMed ID: 12404282
[TBL] [Abstract][Full Text] [Related]
56. [Heterogeneity of the CA125 antigen that coexpresses sialyl Tn and CA19-9 antigens].
Kobayashi H; Ohi H; Shinohara H; Terao T
Nihon Sanka Fujinka Gakkai Zasshi; 1993 Sep; 45(9):980-6. PubMed ID: 8371024
[TBL] [Abstract][Full Text] [Related]
57. [The preparation and clinical use of a radioimmunoassay CA125 kit for the diagnosis of epithelial ovarian cancer].
Liu W
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 1992 Dec; 14(6):469-72. PubMed ID: 1303823
[TBL] [Abstract][Full Text] [Related]
58. Different levels of sialyl-Tn antigen expressed on MUC16 in patients with endometriosis and ovarian cancer.
Akita K; Yoshida S; Ikehara Y; Shirakawa S; Toda M; Inoue M; Kitawaki J; Nakanishi H; Narimatsu H; Nakada H
Int J Gynecol Cancer; 2012 May; 22(4):531-8. PubMed ID: 22367369
[TBL] [Abstract][Full Text] [Related]
59. [The mechanism of the increase in the serum CA125 concentration in patients with endometriosis].
Kobayashi H; Miyake W; Yamashita M; Kanayama N; Hayata T; Kawashima Y
Nihon Sanka Fujinka Gakkai Zasshi; 1988 Apr; 40(4):467-72. PubMed ID: 3163715
[TBL] [Abstract][Full Text] [Related]
60. Clinical significance of a solid-phase immunoradiometrical assay for sialyl SSEA-1 antigen in obstetrics and gynecology.
Ota Y; Inaba N; Shirotake S; Fukazawa I; Okajima Y; Takamizawa H
Asia Oceania J Obstet Gynaecol; 1989 Sep; 15(3):253-9. PubMed ID: 2597088
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
